Yahoo · Aug 13, 2026
Organogenesis (ORGO) Q2 2026 Earnings Call Transcript
CMS policy changes drove 58% revenue decline, but sequential recovery signals stabilization.
OR
NASDAQ · ORGO
Organogenesis Holdings Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$1.34
Up+$0.05 (+3.88%)
Updated Oct 7, 2026, 9:53 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 607.66M
- P/E ratio
- -69.15
- Dividend yield
- 0.00%
- 52-week range
- $1.28 – $2.82
- Volume
- 608.73K
- Avg. volume
- 1.55M
Price performance · ORGO
ORGO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ORGO closed at $1.34 after 21 trading sessions, down 16.25% for the selected period.
- Last close
- $1.34
- Period change
- -16.25%
- Period low
- $1.29
- Period high
- $1.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.30 | $1.35 | $1.29 | $1.34 | 608.73K |
| Oct 5, 2026 | $1.32 | $1.338 | $1.275 | $1.29 | 1.83M |
| Oct 2, 2026 | $1.40 | $1.40 | $1.32 | $1.33 | 536.99K |
| Oct 1, 2026 | $1.38 | $1.43 | $1.37 | $1.40 | 684.63K |
| Sep 30, 2026 | $1.38 | $1.405 | $1.35 | $1.37 | 543.88K |
| Sep 29, 2026 | $1.36 | $1.404 | $1.36 | $1.385 | 469.65K |
| Sep 28, 2026 | $1.38 | $1.39 | $1.35 | $1.38 | 446.32K |
| Sep 25, 2026 | $1.43 | $1.4396 | $1.36 | $1.41 | 609.3K |
| Sep 24, 2026 | $1.45 | $1.46 | $1.39 | $1.42 | 533.69K |
| Sep 23, 2026 | $1.46 | $1.47 | $1.42 | $1.45 | 415.62K |
| Sep 22, 2026 | $1.40 | $1.495 | $1.40 | $1.48 | 412.68K |
| Sep 21, 2026 | $1.41 | $1.415 | $1.38 | $1.40 | 355.87K |
| Sep 18, 2026 | $1.36 | $1.42 | $1.34 | $1.42 | 1M |
| Sep 17, 2026 | $1.42 | $1.42 | $1.355 | $1.36 | 506.86K |
| Sep 16, 2026 | $1.45 | $1.465 | $1.38 | $1.39 | 943.81K |
| Sep 15, 2026 | $1.49 | $1.495 | $1.45 | $1.46 | 445.07K |
| Sep 14, 2026 | $1.49 | $1.51 | $1.45 | $1.50 | 646.88K |
| Sep 11, 2026 | $1.56 | $1.56 | $1.47 | $1.49 | 844.15K |
| Sep 10, 2026 | $1.57 | $1.57 | $1.49 | $1.53 | 912.47K |
| Sep 9, 2026 | $1.58 | $1.59 | $1.55 | $1.57 | 465.74K |
| Sep 8, 2026 | $1.68 | $1.68 | $1.57 | $1.60 | 979.73K |
Latest ORGO news
The latest Smart Investors Daily articles mentioning ORGO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ORGO research
Overview
Company profile and research snapshot.
Company profile
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Truist Securities | Hold | — |
| May 28, 2026 | Truist Securities | Hold | — |
| Mar 26, 2026 | BTIG | Buy | — |
| Feb 27, 2026 | BTIG | Buy | — |
| Dec 26, 2025 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 10, 2026
Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution
The latest update on Organogenesis Holdings centers on a cut to the assessed fair value and price target from US$3.00 to US$2.00, which marks a reduction of around one third. Analysts framing this shift with Hold ratings describe a mix of potential opportunity and clear near term challenges. This reflects a more cautious but still balanced view of risk and reward. As you read on, you will see how this revised price target fits into the evolving narrative around guidance, reimbursement...
Yahoo · Aug 8, 2026
Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?
In August 2026, Organogenesis Holdings Inc. reported second-quarter revenue of US$43.76 million and a net loss of US$96.27 million, alongside sharply reduced full-year 2026 revenue guidance and a US$75.00 million at-the-market equity offering. These results highlighted a very large year-over-year revenue contraction and a significantly wider loss per share, even as new Affinity clinical data added support to the company’s chronic wound care portfolio. We’ll now examine how this steep revenue...
Yahoo · Aug 7, 2026
Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary
Moby summary of Organogenesis Holdings Inc.'s Q2 2026 earnings call
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
